PHAT logo

PHATPhathom Pharmaceuticals Inc

$10.53
$0.16
(1.54%)
Today
Updated: 10:35 AM EDT
EarningsAug 6
Mkt Cap$827.07M
Vol57,876.00
News
all
press releases
Phathom Pharmaceuticals (NASDAQ:PHAT) Stock Price Up 7.5% - Should You Buy?
Phathom Pharmaceuticals (NASDAQ:PHAT) Shares Up 7.5% - Should You Buy...
MarketBeat
News Placeholder
More News
News Placeholder
Phathom Pharmaceuticals (NASDAQ:PHAT) Releases Earnings Results, Misses Estimates By $0.01 EPS
Phathom Pharmaceuticals (NASDAQ:PHAT - Get Free Report) issued its quarterly earnings data on Thursday. The company reported ($0.18) EPS for the quarter, missing the consensus estimate of ($0.17) by...
MarketBeat
News Placeholder
Phathom Pharmaceuticals Q1 Earnings Call Highlights
Phathom Pharmaceuticals (NASDAQ:PHAT) reported first-quarter 2026 net revenue of $58.3 million, more than doubling the $28.5 million recorded in the same period a year ago, as the company emphasized...
MarketBeat
News Placeholder
Phathom Pharmaceuticals (NASDAQ:PHAT) Stock Price Down 16.2% After Earnings Miss
Phathom Pharmaceuticals (NASDAQ:PHAT) Shares Down 16.2% on Disappointing Earnings...
MarketBeat
News Placeholder
Phathom Pharmaceuticals Reports Q1 2026 Results: Full Earnings Call Transcript
read more...
Benzinga
News Placeholder
Phathom Pharmaceuticals, Inc. (PHAT) Reports Q1 Loss, Tops Revenue Estimates
Phathom Pharmaceuticals (PHAT) delivered earnings and revenue surprises of -5.88% and +2.76%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?
Zacks
News Placeholder
Phathom Pharmaceuticals (PHAT) Projected to Post Earnings on Thursday
Phathom Pharmaceuticals (NASDAQ:PHAT) will be releasing its Q1 2026 earnings before the market opens on Thursday, April 30. (View Earnings Report at https://www.marketbeat.com/earnings/reports/2026-4-30-phathom-pharmaceuticals-inc-stock...
MarketBeat
News Placeholder
Phathom Pharmaceuticals (NASDAQ:PHAT) Shares Down 6.8% - Time to Sell?
Phathom Pharmaceuticals (NASDAQ:PHAT) Trading Down 6.8% - Time to Sell...
MarketBeat
News Placeholder
Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT) Receives Consensus Rating of "Moderate Buy" from Analysts
Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT - Get Free Report) has received a consensus recommendation of "Moderate Buy" from the nine analysts that are presently covering the firm, MarketBeat.com...
MarketBeat
News Placeholder
Hennion & Walsh Asset Management Inc. Buys New Shares in Phathom Pharmaceuticals, Inc. $PHAT
Hennion & Walsh Asset Management Inc. bought a new position in Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT - Free Report) in the 4th quarter, according to the company in its most recent disclosure with the SEC. The institutional investor bought 114,981 shares of the company's stock, valued at appro...
MarketBeat
<
1
2
...
>

Advertisement|Remove ads.